This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Investors Should Retain McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.
Allscripts to Fortify Middle East Foothold With New Project
by Zacks Equity Research
Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.
Here's Why Investors Should Bet on Cooper Companies (COO) Now
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.
Here's Why Investors Should Bet on Merit Medical (MMSI) Now
by Zacks Equity Research
Merit Medical's (MMSI) upbeat guidance for 2019 is indicative of the company's brighter prospects.
Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS
by Zacks Equity Research
Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.
Here's Why You Should Invest in AngioDynamics Stock Now
by Zacks Equity Research
Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.
Here's Why Momentum Investors Will Love Idexx Laboratories (IDXX)
by Zacks Equity Research
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.
Bright Near-Term Outlook for Medical Instruments Industry
by Zacks Equity Research
Growing medical awareness and economic prosperity have been enhancing the uptake of medical instruments in the emerging economies.
IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View
by Zacks Equity Research
IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 8.89% and 0.69%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
ZBH & IDXX Q4 Earnings on Feb 1: Here are the Key Predictions
by Zacks Equity Research
The global medical device space is passing through a rewarding phase for a considerable period of time in terms of research and development (R&D) plus regulatory progress.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Idexx (IDXX) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Idexx Laboratories (IDXX) Q3 Earnings Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 7.14% and -0.03%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
IDEXX Laboratories (IDXX) Beats on Q3 Earnings, EPS View Up
by Zacks Equity Research
IDEXX Laboratories' (IDXX) stellar performance in Q3 reflects strong sales at the CAG business.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.
Idexx Laboratories (IDXX) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Idexx (IDXX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.
IDEXX Gains Ground on Solid CAG Business Amid Forex Woes
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.
Why Is Idexx (IDXX) Up 5.3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Nasdaq ETF Hits New Highs: 5 Stocks Up More Than 50%
by Sweta Killa
Though most of the stocks in the Nasdaq ETF portfolio delivered strong returns so far this year, a few were the real stars, having gained more than 50%.